Walter Moos

MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.

Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA.

Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA.

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Aprinoia Therapeutics, Inc. operates as a drug discovery and early development company. The company was founded by Ming-Kuei Jang in May 20, 2015 and is headquartered in Taipei, Taiwan.

Alnis Biosciences, Inc. is a biopharmaceutical company that develops therapeutics from its nanoparticle technology platform. The company was founded on May 29, 2007 and is headquartered in Raleigh, NC.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Axiom Biotechnologies, Inc. discovered and developed drugs through use of its proprietary human cell-based physiogenomics technology and focused on cancer, acid reflux disease, and obesity. The company was headquartered in San Diego, CA.

Mimotopes Pty Ltd is an industry leader in the peptide and discovery chemistry sector. Mimotopes develops, markets and distributes high quality biochemical products and services for the life-science sector. Their customers range from small labs and universities worldwide, to large multinational drug discovery companies. Their core competence covers the following areas: ' Custom Peptides Mimotopes' custom peptides are synthesized in modern, automated synthesizers using advanced solid phase techniques. The value in using Mimotopes custom peptides is not only that they offer a wide range of peptide lengths, purities and quantities. Their customers can also draw on the exceptional experience of their technical staff, who consult with them to design the peptide application that gives the best possible research outcome. ' PepSets Peptide Libraries Peptide libraries for various screening applications in Proteomics, Immunology and Drug Discovery. PepSets peptide libraries provide researchers with a rapid and cost effective solution for an immense range of bioactivity screening purposes. These sets of custom synthesized peptides enable fast, efficient results. ' Peptide Reagents High-quality amino acids and peptide synthesis reagents. The same reagents that Mimotopes uses in its in-house production system. ' SynPhase Lanterns Modular solid phase supports for organic synthesis, combinatorial chemistry, peptide chemistry, molecule scavenging and affinity applications. Convenient to handle, SynPhase Lanterns are the unique and reliable alternative to using conventional resins for solid-phase synthetic chemistry. Not only do SynPhase Lanterns provide superior reaction kinetics, but their unrivalled ease of handling results in less errors, better traceability and ultimately, faster, more accurate results.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.